import MedQuickFactBar from '../MedQuickFactBar.js'

# SGLT2 inhibitors

<MedQuickFactBar
a1cText={`0.5-1%`}
rountineText={`Daily`}
lowBloodSugarText={`No`}
weightChangeText={`Loss`}
heartBenefitText={`Benefit`}
costText={`High`}
/>

**Oral medication.**

**Does not cause low blood sugar (hypoglycemia).**

SGLT2 stands for “Sodium-glucose co-transporter 2”

Several different medications in this class

> - Empagliflozin (Jardiance)
> - Canagliflozin (Farxiga)
> - Dapagliflozin (Invokana)
> - Ertugliflozin (Steglatro)

**Works by** blocking sugar reuptake from the urine
back into the kidneys, causing glucose to be urinated out of the body.

**Efficacy** Intermediate

**Pros**

> - Heart disease benefit with empagliflozin and canagliflozin
> - Assists with mild weight loss
> - Does not cause hypoglycemia
> - Protection from diabetic kidney injury

**Cons**

> - Relatively expensive (no generics)
> - Can cause urinary tract and vaginal/groin yeast infections
> - Mild dizziness upon standing if not adequately hydrating
> - Extremely rare foot and leg amputation with canagliflozin only
